At a glance
ClinicalIndex Comparison Record- ✓Aged 40-65 years
- ✓Non-hysterectomised women who have undergone breast surgery (Group 1) or healthy non-hysterectomised women (Group 2)
- ✓Women on aromatase inhibitors within preceding 12 weeks (Group 1 only)
- ✕Previous knee injury requiring non-weight bearing treatment for >24 hours or knee surgery including arthroscopy
- ✕Contraindication to MRI including pacemaker, metal sutures, shrapnel, or iron filings in eye
- ✕Claustrophobia
- ✕Prior tamoxifen treatment for >8 weeks (Group 1 only)
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Assessment of Knee Joint Articular Cartilage Volume Change, Bone Loss and Change in Body Composition in Women Treated With Anastrozole or Letrozole and Comparison With Untreated Controls
In Brief
An observational study evaluating aromatase inhibitors (letrozole, anastrozole) for Arthralgia. Completed, enrolled 115 participants across 1 site.
Detailed Summary
Many women with breast cancer are treated with a class of drugs called aromatase inhibitors (mainly letrozole or anastrozole), which lowers the amount of estrogen being produced in the body. Women on aromatase inhibitors appear to experience joint pains and arthralgia. The aim of this study is to determine whether the joint pains experienced by some women on aromatase inhibitors is associated with more defects in their cartilage, compared to women not receiving this therapy. Using the magnetic resonance imaging (MRI) technique, the knee joint will be examined to assess changes in cartilage volume over time.
Study Details
Timeline
Interventions
Women prescribed an aromatase inhibitor by their clinician were compared with healthy controls in the community who had been recruited to a prior study